RapidASCVD: PREVENT ASCVD Risk

RapidASCVD accurately estimates 10-year ASCVD (atherosclerotic cardiovascular disease) and cardiovascular risk using the American Heart Association (AHA) PREVENT equations. The user interface has been optimized for speed so that busy clinicians are able to quickly calculate risk scores for patients in the fastest amount of time possible -- usually within about 10–15 seconds. RapidASCVD estimates the 10-year probability of a first-time (primary) cardiovascular event in adults aged 30–79 years without known cardiovascular disease. In addition to 10-year ASCVD risk, the app reports 10-year risk of total cardiovascular disease (CVD), heart failure, coronary heart disease (CHD), and stroke, along with a comparison against optimal risk factors. These estimates are not appropriate for use in patients who have already had an established cardiovascular event. RapidASCVD has been extensively tested for accuracy against the AHA PREVENT equations (Circulation. 2024; doi: 10.1161/CIRCULATIONAHA.123.067626, including the October 2026 HbA1c correction, doi: 10.1161/CIR.0000000000001491), which are derived from the following variables: • Age • Sex • Total cholesterol (mg/dL or mmol/L) • HDL cholesterol (mg/dL or mmol/L) • Systolic blood pressure • Body mass index (BMI, with built-in height/weight calculator) • Estimated GFR (eGFR, with built-in 2021 CKD-EPI creatinine calculator) • History of diabetes mellitus • Current smoking status • Presence of antihypertensive therapy • Presence of statin therapy Optional risk factors: • Hemoglobin A1c (HbA1c) • Urine albumin-to-creatinine ratio (UACR) • Social Deprivation Index (SDI, by category or built-in offline 5-digit US ZIP code lookup) Risk categorization and statin intensity guidance are aligned with the 2026 ACC/AHA Guideline on the Management of Dyslipidemia (doi: 10.1161/CIR.0000000000001423). This clinical tool operates 100% offline, stores no patient data, and is intended to be used in conjunction with clinical judgment and shared decision-making.